Clinical Trial Update: Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 clinical trial evaluating alemtuzumab with CHOP chemotherapy in patients with aggressive peripheral T-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• CAMPATH (ALEMTUZUMAB)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Oncovin (vincristine)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Peripheral T-cell Lymphomas | Phase 1, Phase 2 | Status: COMPLETED